Today's Research Daily features a real-time update on the Q4 earnings season and fresh Chevron (CVX), Merck (MRK), QUALCOMM ...

Ursinus College has received a $4 million pledge that when realized will be among the largest gifts ever to the 156-year-old ...

Louisiana has six seats in the House of Representatives, four Republican and two Democrat. There are three ways for a sitting ...

Merck has a positive record of earnings surprises ... it is benefiting from investments toward building a licensing program in mobile. Qualcomm received a favorable verdict in a legal dispute ...

BL/ - The names of the most important Chief Sustainability Officers of Europe were announced at the Futur/io C ...

A warning on D.E.I.: The Trump administration on Wednesday threatened tens of thousands of federal employees with “adverse consequences” if they fail to report on colleagues who defy orders to purge ...

The first week of President Donald Trump’s second term dealt several body blows to public health. Among a flurry of executive ...

GSK’s share price has been pressured recently from several negative events, but this may leave a bargain to be had. I've ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is ...

The Bull and Gelding Sale started on Tuesday with the sifting and grading of all range-ready calving ease and bulls. It ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.